Clinical Trial

Motixafortide for MRD Sensitization in AML

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a pilot phase I study evaluating the effect of motixafortide on determination of measurable residual disease (MRD) level in patients with acute myeloid leukemia (AML) who have completed induction treatment. Consenting and eligible patients will undergo standard of care (SOC) bone marrow and peripheral blood assessments with SOC MRD assays, followed by a single injection of motixafortide. Ten to 14 hours after injection, the patient will undergo peripheral blood collection for the same applicable MRD tests
Protocol Amendment History 5 changes
critical Recruitment opened 2026-07-25
notable Primary completion pushed: 2028-06-02 -> 2028-08-02 2026-07-07
minor Completion pushed: 2029-12-02 -> 2030-02-02 2026-07-07
notable Primary completion pushed: 2028-04-02 -> 2028-06-02 2026-04-10
minor Completion pushed: 2029-10-02 -> 2029-12-02 2026-04-10
Trial Details
NCT Number NCT07392970
Lead Sponsor Washington University School of Medicine
Collaborators: Gamida Cell ltd
Conditions Acute Myeloid Leukemia, Measurable Residual Disease
Enrollment 10 participants
Start Date 2026-07-23
Primary Completion 2028-08-02 (estimated)
Study Completion 2030-02-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-24